1620P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials.

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Mesothelioma
Thoracic malignancies
Presenter Susana Cedres
Citation Annals of Oncology (2017) 28 (suppl_5): v568-v572. 10.1093/annonc/mdx389
Authors S. Cedres1, A. Martinez Marti1, A. Navarro1, N. Pardo1, J. Remon1, I. Matos1, M. Ochoa de Olza1, C. Hierro1, J. Martin Liberal1, J.M. Miquel1, C. VIAPLANA2, G. Villacampa Javierre2, R. Dienstmann2, E. Felip Font1
  • 1Medical Oncology, Vall d´Hebron University Hospital/Vall d´Hebron Institute Oncology, 08035 - Barcelona/ES
  • 2Oncology Data Science (odyssey) Group, Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES



The increasing incidence and poor outcome associated with MPM requires identification of effective treatment options. Initial data have demonstrated beneficial effects of IO in MPM, however recent results of clinical studies with immune checkpoint inhibitors (CPI) are not so encouraging. The aim of this study is to evaluate the outcomes of p with MPM treated with immunotherapy in clinical trials at our institution.


20 MPM p treated with IO at Vall d´Hebron Institute of Oncology between September 2012 and December 2016 were reviewed. Survival data were calculated by the Kaplan-Meier method. The associations of type of immunotherapy with outcomes were assessed with Cox regression models.


Patient’s characteristics: median age 63 years (45-77 years), males: 62%, performance status (PS) 1:86%, asbestos exposure: 82%, stage III at diagnosis: 51%, epithelial subtype: 82%. All p were treated with chemotherapy, 90% received cisplatin plus pemetrexed as first line with median progression free survival (PFS) of 9.1 months (m;CI95% 7.6-10.7). Clinical trial with IO was offered as second-line regimen in 65% and third line in 35%. Target of IO was CTLA4: 60%, PD-1: 25% and other CPI single agent 15% (LAG3, GITR, CD40). Overall, disease control rate at 4 months was 40%. Reason for treatment discontinuation was toxicity in 20% of cases. Median PFS with IO in second line was 5.6 m (2.7-NR) and in third line 3.7 m (1.4-NR, p = 0.77). Different outcomes were seen according to target selected: with PD-1 median PFS of 8.6 m (4.2-NR) and with CTLA4 of 4.2 m (2.2-NR), significantly longer than 1.9 m (0.7-NR) with other CPI (p  0.05 all comparisons).


In our single institution series of previously treated MPM, IO associates with prolonged disease control in a subgroup of patients, with longest benefit seen with anti PD-1 therapies. Further research with predictive biomarkers of IO in MPM is needed.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.